Loading...
XLON
BXP
Market cap318mUSD
Oct 09, Last price  
51.50GBP
1D
-4.63%
1Q
5.10%
Jan 2017
1.16%
IPO
109.88%
Name

Beximco Pharmaceuticals Ltd

Chart & performance

D1W1MN
XLON:BXP chart
P/E
6.41
P/S
0.84
EPS
13.07
Div yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
14.24%
Revenues
44.39b
+13.05%
3,326,972,7173,702,289,1383,596,989,5834,010,143,0564,868,245,7826,490,813,7427,890,181,3219,289,115,28410,490,699,09411,206,885,67712,965,506,87315,508,776,97217,716,716,85522,816,629,79525,611,947,65529,493,573,86934,669,172,05239,266,662,00044,391,604,000
Net income
5.83b
+26.34%
489,230,534470,691,818353,013,003545,344,689624,794,4431,051,732,8251,198,424,9921,319,389,3281,404,762,7801,528,297,5731,954,284,5162,226,695,1242,536,543,9483,033,402,3333,514,687,3015,127,693,7115,123,136,7124,614,066,0005,829,529,000
CFO
8.36b
+37.47%
311,494,2431,079,631,622340,671,788880,778,163520,885,0171,198,514,4541,246,031,9171,857,380,0702,130,330,7582,215,980,4022,112,852,5982,633,964,9861,819,113,9232,959,916,9045,542,487,2216,023,263,9555,214,176,0006,084,787,0008,364,466,317
Dividend
Jul 31, 20262.32 GBP/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Established in 1976 and headquartered in Dhaka, Bangladesh, Beximco Pharmaceuticals Limited is a prominent company engaged in the production and distribution of generic pharmaceutical formulations and active pharmaceutical ingredients (APIs). The firm’s extensive product line addresses a wide range of therapeutic areas, including treatments for allergic disorders, pain and fever, various infections (antibacterial and antiviral), cardiovascular conditions, central nervous system ailments, respiratory illnesses, endocrine disorders, diabetes, gastrointestinal problems, hormonal therapies, oncology, musculoskeletal issues, and skin conditions. Its offerings also encompass eye care products, vitamin and mineral supplements, and intravenous fluids. These medications are supplied in a comprehensive array of dosage forms, such as solids, liquids, creams, ointments, suppositories, metered-dose and dry powder inhalers, nasal sprays, sterile injectables (including lyophilized forms), and large volume intravenous fluids. Beyond its own diverse portfolio, Beximco Pharmaceuticals provides contract manufacturing services to other companies and actively exports its products internationally.

Key people

Ahmed Rahman
Chairman of the Board
Mohammad Ali Nawaz
Chief Financial Officer · since 2003
Rabbur Reza
Chief Operating Officer · since 2009
Managing Director · since 2024
M A Arshad Bhuiyan
General Manager of Human Resource
Mohammad Asad Ullah
Executive Director, Company Secretary
Zakaria Chowdhury
Director of Marketing, Head of Distribution Services · since 2021
Rizvi Ul Kabir
Director of Marketing
Afsar Ahmed
Director - Commercial
Selina Akter
Executive Director - Department of Medical Affairs
Jamal Choudhury
Director - Accounts and Finance · since 2021
Member of the Management Committee, Director
Shawkat Haider
Executive Director - Business Development and Corporate Affairs
Roksana Hassan
Executive Director - Financial Compliance, Audit and Internal Control
Shamim Momtaz
Director - Manufacturing
Lutfur Rahman
Director - Manufacturing · since 2021
Mohd. Tahir Siddique
Director - Quality · since 2021
Ahmed Rahman
Vice Chairman of the Board
Reem Shamsuddoha
Director · since 2020
IPO date
Oct 21, 2005
Employees
5,500
Domiciled in
BD
Incorporated in
BD
Headquarters & legal address
NO. 19, DHANMONDI R/A, ROAD NO. 7
DHAKA, C 1205
BD
Previous name
BEXIMCO PHARMACEUTICALS LIMITED

Valuation

Title
BDT in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT